US Bancorp DE Cuts Stock Holdings in Repligen Co. (NASDAQ:RGEN)

US Bancorp DE lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 34.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,032 shares of the biotechnology company’s stock after selling 5,261 shares during the quarter. US Bancorp DE’s holdings in Repligen were worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norden Group LLC boosted its stake in shares of Repligen by 38.7% in the first quarter. Norden Group LLC now owns 2,972 shares of the biotechnology company’s stock valued at $547,000 after buying an additional 830 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Repligen by 173.3% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 2,848 shares of the biotechnology company’s stock worth $524,000 after purchasing an additional 1,806 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in shares of Repligen by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 45,443 shares of the biotechnology company’s stock worth $8,358,000 after purchasing an additional 588 shares during the period. Hilltop National Bank purchased a new position in shares of Repligen in the 1st quarter valued at about $154,000. Finally, Lisanti Capital Growth LLC lifted its stake in shares of Repligen by 59.6% in the first quarter. Lisanti Capital Growth LLC now owns 3,870 shares of the biotechnology company’s stock valued at $712,000 after purchasing an additional 1,445 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

Repligen stock opened at $143.88 on Friday. The firm’s 50-day moving average is $141.77 and its two-hundred day moving average is $145.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a market capitalization of $8.06 billion, a P/E ratio of -3,596.10, a P/E/G ratio of 4.01 and a beta of 0.96. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13.

Analyst Ratings Changes

A number of research analysts have issued reports on RGEN shares. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.